Topas Therapeutics is a spin-off from Evotec, a leading global biopharmaceutical company, which together with partners is driving drug discovery and development at Topas. Topas has developed a unique technology to induce antigen-specific immune tolerance. This makes it possible to treat autoimmune diseases, allergies and drug-induced immune reactions more efficiently and safely. The company is currently conducting a phase 2 clinical trial in the field of coeliac disease.
At Topas Therapeutics, we're pioneering a game-changing approach to treat autoimmune disorders, allergies, and drug-induced immune reactions. Gimv's investment highlights our shared commitment to this innovative solution.